Genzyme seeks approval for new kidney treatment

[okarol]

Genzyme seeks approval for new kidney treatment

Thursday December 21, 10:11 am ET - bizjournals.com

Genzyme Corp. wants federal regulators to approve a new treatment for patients with chronic kidney disease on dialysis.

The Cambridge, Mass. company (Nasdaq: Genz - News) announced on Thursday that it has filed a new drug application with the U.S. Food and Drug Administration seeking approval of Sevelamer carbonate.

The drug, to be known commercially as Renvela, is intended to replace the company's Renagel as a next generation phosphate binder. The drug is intended to control serum phosphorus in patients with chronic kidney disease on dialysis.

Genzyme is also testing Renvela as a treatment for patients with chronic kidney disease who have not progressed to dialysis. In addition, the drug, to be initially marketed in tablet form, is being tested in powder form.

Published December 21, 2006 by the Boston Business Journal

URL: http://biz.yahoo.com/bizj/061221/1393274.html?.v=1

[BigSky]

Stuff like this makes you wonder if they really improved the product or they are just slightly changing it to keep a stranglehold on their patient of the drug to keep if from going generic.

[Sluff]

Of course it's all about the money.